For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Royalties and license fees | - | - | - | 0 |
| Total revenues | 0 | 0 | 0 | - |
| Research and development | 6,298,000 | 5,834,000 | 3,370,000 | 3,695,000 |
| General and administrative | 7,284,000 | 7,543,000 | 6,433,000 | 13,481,000 |
| Total operating expenses | 13,582,000 | 13,377,000 | 9,803,000 | 17,176,000 |
| Loss from operations | -13,582,000 | -13,377,000 | -9,803,000 | -17,176,000 |
| Foreign currency transaction loss (gain) | 70,000 | 131,000 | -89,000 | 119,000 |
| Interest income, net | 1,594,000 | 1,390,000 | 1,011,000 | 1,036,000 |
| Other expense, net | -17,000 | 19,000 | -84,000 | -123,500* |
| Loss on extinguishment of liabilities | 0 | 0 | - | -2,500* |
| Unrealized loss on investment | - | - | - | 0* |
| Total other income, net | 1,647,000 | 1,540,000 | 838,000 | 1,029,000 |
| Net loss | -11,935,000 | -11,837,000 | -8,965,000 | -16,147,000 |
| Unrealized foreign currency translation gain (loss) | - | - | 89,000 | - |
| Total other comprehensive income (loss) | - | - | 89,000 | - |
| Total comprehensive loss | - | - | -8,876,000 | - |
| Net loss attributable to common shareholders | -11,935,000 | -11,837,000 | - | - |
| Basic EPS | -0.24 | -0.26 | -0.22 | -0.446 |
| Diluted EPS | -0.24 | -0.26 | -0.22 | -0.446 |
| Basic Average Shares | 49,386,203 | 45,970,516 | 41,521,280 | 36,209,271* |
| Diluted Average Shares | 49,386,203 | 45,970,516 | 41,521,280 | 36,209,271* |
Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc. (BNTC)